

Hemgenix as First Gene Therapy for Treatment of Haemophilia B

Mr. Sachin Navale, Miss. Kaveri Bhosale, Mr. Mahesh Mohite and Mrs. Swapnali Navale

Nootan College of Pharmacy, Kavathe Mahankal, Sangli, Maharashtra, India

Abstract: We know about haemophilia B is an inheritable bleeding complaint performing from missing or inadequate situations of blood clotting Factor IX, a protein demanded to produce blood clots to stop bleeding. Haemophilia B is a rare, lifelong bleeding complaint caused by a single gene disfigurement, performing an inadequate product of factor IX, a protein primarily produced by the liver that helps blood clots form. Treatments for moderate to severe haemophilia B include precautionary infusions of factor IX relief remedy to temporarily replace or condense low situations of blood-clotting factor and, while these curatives are effective, those with haemophilia B must cleave to strict, lifelong infusion schedules. But lately US FDA authorize hemegenix for haemophilia. the first and only one-time gene remedy for applicable grown-ups with haemophilia. Hemgenix is approved for the treatment of grown-ups with haemophilia B who presently use factor IX Prophylaxis remedy.

Keywords: Haemophilia B, Prophylaxis, X chromosome, Etranacogene dezaparovec

REFERENCES

- [1]. Cristina Santoro, Gabriele Quinta Valle, Erminia Baldacci, Antonietta Ferrett, Federica Riccardi: Inhibitors in Hemophilia B, Semin Thromb Hemost 2018; 44(06): 578-589
- [2]. F. R. Rosendaal, Hemophilia B: Molecular pathogenesis and mutation analysis, 07 April 2015.
- [3]. Annette Von Drygalski, Adam Giermasz, Giancarlo Castaman, Nigel S. Key, Susan Lattimore, Frank W. G. Leebeek, Wolfgang Miesbach, Michael Recht Alison Long, Robert Gut, Eileen K. Sawyer, Steven W. Pipe, Etranacogene dezaparovec (AMT-061 phase 2b): normal/near normal fix activity and bleed cessation in hemophilia B, OCTOBER 30, 2019.
- [4]. Annette Von Drygalski, Adam Giermasz, Giancarlo Castaman, Nigel S. Key, Susan Lattimore, Frank W. G. Leebeek, Wolfgang Miesbach, Michael Recht Alison Long, Robert Gut, Eileen K. Sawyer, Steven W. Pipe, Etranacogene dezaparovec (AMT-061 phase 2b): normal/near normal fix activity and bleed cessation in hemophilia B, October 30 2019.
- [5]. Courtney D. Thornburg, Etranacogene dezaparovec for hemophilia B gene therapy, First published online on November 24, 2021.
- [6]. CSL. U.S. Food and Drug Administration approves CSL's hemgenix (etranacogene dezaparovec-drlb), the first gene therapy for hemophilia B. Nov. 22, 2022. Available at: www.csl.com/news/2022/fda-hemgenix. Accessed Nov. 22, 2022.
- [7]. F. R. Rosendaal, Hemophilia B: Molecular pathogenesis and mutation analysis, 07 April 2015.
- [8]. Cristina Santoro, Gabriele Quintavalle, Erminia Baldacci, Antonietta Ferrett, Federica Riccardi Inhibitors in Hemophilia B, Semin Thromb Hemost 2018; 44(06): 578-589
- [9]. Giancarlo Castaman: The benefits of prophylaxis in patients with hemophilia B, Received 19 Apr 2018, Accepted 13 Jun 2018, Accepted author version posted online: 18 Jun 2018, Published online: 18 Jul 2018.
- [10]. U.S. approves first gene therapy to treat adults with hemophilia B [press release]. Nov. 22, 2022. Available at: www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b. Accessed Nov. 22, 2022.

- [11]. I. M. Verma, L. Naldini, T. Kafri, H. Miyoshi, M. Takahashi, U. Blömer N. Somia, L. Wang & F. H. Gage , Gene Therapy: Promises, Problems and Prospects, conference paper.
- [12]. Thomas Wirth Nigel Parker Seppo Ylä-Herttuala, History of gene therapy, Volume 525, Issue 2, 10 August 2013.
- [13]. U.S.FDA approves first gene therapy to treat adults with hemophilia B [press release]. Nov. 22, 2022. Available at: www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b. Accessed Nov. 22, 2022.
- [14]. U.S. FDA approves first gene therapy to treat adults with hemophilia B [press release]. Nov. 22, 2022. Available at: www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b. Accessed Nov. 22, 2022.
- [15]. U.S. FDA approves first gene therapy to treat adults with hemophilia B [press release]. Nov. 22, 2022. Available at: www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b. Accessed Nov. 22, 2022.
- [16]. U.S. FDA approves first gene therapy to treat adults with hemophilia B [press release]. Nov. 22, 2022. Available at: www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b. Accessed Nov. 22, 2022.
- [17]. F. Bernadi A, Dolce M Pinnotti A, D. Shapiro E, Santagostino, F. Peyvandi A, Batorovam M, Lapecorella, J.F. Schved, J. Ingerslev, Major differences in bleeding symptoms between factor VII deficiency and hemophilia B, 21 April 2009.
- [18]. U.S. FDA approves first gene therapy to treat adults with hemophilia B [press release]. Nov. 22, 2022. Available at: www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b. Accessed Nov. 22, 2022.